New hope for rare blood cancer: drug cocktail targets resistant lymphoma
NCT ID NCT07209163
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether combining tazemetostat with either linperlisib or golidocitinib can safely shrink tumors in people with relapsed or refractory peripheral T-cell lymphoma. About 48 adults who have already tried at least one other treatment will receive the drugs by mouth. The goal is to find a better option for patients who have few choices left.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tazemetostat combined with linperlisib or golidocitinib
- What this could lead to
- If successful, this could offer a new treatment option for people with relapsed or refractory peripheral T-cell lymphoma who have few alternatives.
- What could go wrong
- This is an early-phase trial with a small number of participants (48). The combination may not work better than existing treatments, and side effects could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot lymphoma earlier?
- Can a Five-Drug combo tame a tough lymphoma without standard chemo?
- Can a targeted pill boost Chemotherapy's punch against a rare lymphoma?
- A microchip implanted in tumors could reveal which drugs work best
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Experimental drug combo aims to tackle tough lymphoma